Burns LH - Search Results

1

Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein.

Wang HY, Burns LH. Wang HY, et al. Among authors: burns lh. J Neurobiol. 2006 Oct;66(12):1302-10. doi: 10.1002/neu.20286. J Neurobiol. 2006. PMID: 16967511

2

PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis.

Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns LH. Wang HY, et al. Among authors: burns lh. Neurobiol Aging. 2017 Jul;55:99-114. doi: 10.1016/j.neurobiolaging.2017.03.016. Epub 2017 Mar 31. Neurobiol Aging. 2017. PMID: 28438486

3

Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine.

Wang HY, Burns LH. Wang HY, et al. Among authors: burns lh. PLoS One. 2009;4(1):e4282. doi: 10.1371/journal.pone.0004282. Epub 2009 Jan 27. PLoS One. 2009. PMID: 19172190 Free PMC article.

4

High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence.

Wang HY, Frankfurt M, Burns LH. Wang HY, et al. Among authors: burns lh. PLoS One. 2008 Feb 6;3(2):e1554. doi: 10.1371/journal.pone.0001554. PLoS One. 2008. PMID: 18253501 Free PMC article.

5

Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.

Wang HY, Friedman E, Olmstead MC, Burns LH. Wang HY, et al. Among authors: burns lh. Neuroscience. 2005;135(1):247-61. doi: 10.1016/j.neuroscience.2005.06.003. Neuroscience. 2005. PMID: 16084657

6

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW. Largent-Milnes TM, et al. Among authors: burns lh. J Pain. 2008 Aug;9(8):700-13. doi: 10.1016/j.jpain.2008.03.005. Epub 2008 May 12. J Pain. 2008. PMID: 18468954 Free PMC article.

7

Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A.

Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, Burns LH. Wang HY, et al. Among authors: burns lh. J Neurosci. 2012 Jul 18;32(29):9773-84. doi: 10.1523/JNEUROSCI.0354-12.2012. J Neurosci. 2012. PMID: 22815492 Free PMC article.

8

PTI-609: a novel analgesic that binds filamin A to control opioid signaling.

Burns LH, Wang HY. Burns LH, et al. Recent Pat CNS Drug Discov. 2010 Nov;5(3):210-20. doi: 10.2174/157488910793362386. Recent Pat CNS Drug Discov. 2010. PMID: 20726836 Review.

9

Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.

Leri F, Burns LH. Leri F, et al. Among authors: burns lh. Pharmacol Biochem Behav. 2005 Oct;82(2):252-62. doi: 10.1016/j.pbb.2005.08.008. Epub 2005 Sep 21. Pharmacol Biochem Behav. 2005. PMID: 16182352

10

Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.

Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Chindalore VL, et al. Among authors: burns lh. J Pain. 2005 Jun;6(6):392-9. doi: 10.1016/j.jpain.2005.01.356. J Pain. 2005. PMID: 15943961 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results